InvestorsHub Logo
Followers 2
Posts 1360
Boards Moderated 0
Alias Born 01/05/2018

Re: None

Tuesday, 02/06/2018 5:48:07 PM

Tuesday, February 06, 2018 5:48:07 PM

Post# of 21540
I don't know if this has been posted here before, but I found two noteworthy paragraphs about the synthetic Bryostatin 1 here: https://news.stanford.edu/2017/10/12/chemical-method-boosts-supply-key-drug-compound/

"The team members have now produced over 2 grams of bryostatin 1, and once production is scaled up, Wender said, they expect manufacturers could produce about 20 grams per year, enough to cover clinical and research needs. That is a bit more than was ever extracted from B. neritina and enough to treat about 20,000 cancer patients or 40,000 Alzheimer’s patients."

"Stanford University has filed a provisional patent application on the technology, which has been licensed by Neurotrope BioScience for the treatment of neurological disorders. An option to license has been granted by Stanford University to Bryologx Inc. for use in HIV/AIDS eradication and cancer immunotherapy. Wender is an adviser to both companies and a co-founder of the latter."

Apparently 1 gram of Bryostatin 1 can treat about 2000 AD patients, which means that if you want to treat the 5+ million Americans suffering from AD right now, you would need 2,5 kilograms of this stuff, or to put it differently, enough to fit inside a big soda bottle and two soda cans.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News